Prostate cancer subtypes, intratumor heterogeneity and genome evolution
Prostate cancer can be lethal, but is more commonly indolent, with PSA screening having led to over-diagnosis and overtreatment. A clinically important question is how to distinguish lethal from indolent disease. Our lab was among the first to identify clinically-relevant gene-expression and genomic subtypes of prostate cancer. Our recent efforts have focused on characterizing “5q/6q” prostate cancer, a TMPRSS2-ERG fusion-negative molecular subtype characterized by deletions on 5q (CHD1) and 6q, together with SPOP mutation. Ongoing studies, in collaboration with Jim Brooks (Urology) and Rob West (Pathology), seek to define intratumor heterogeneity and genome evolution, with respect to distinguishing lethal from indolent cancers.